Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Mise à jour : Il y a 4 ans
Référence : NCT01359969

Femme et Homme

Extrait

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.


Critère d'inclusion

  • hereditary angioedema